Iridex Corp. Company Profile (NASDAQ:IRIX)

About Iridex Corp.

Iridex Corp. logoIRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company's ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.

Industry, Sector and Symbol:
  • Sector: Computer and Technology
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: IRIX
  • CUSIP:
Key Metrics:
  • Previous Close: $12.70
  • 50 Day Moving Average: $14.35
  • 200 Day Moving Average: $13.81
  • 52-Week Range: $7.50 - $16.64
  • Trailing P/E Ratio: 195.38
  • Foreward P/E Ratio: 44.10
  • P/E Growth: -15.87
  • Market Cap: $128.50M
  • Outstanding Shares: 10,118,000
  • Beta: 0.73
  • Net Margins: 1.43%
  • Return on Equity: 1.93%
  • Return on Assets: 1.55%
  • Current Ratio: 3.77%
  • Quick Ratio: 2.37%
Additional Links:
Companies Related to Iridex Corp.:

Analyst Ratings

Consensus Ratings for Iridex Corp. (NASDAQ:IRIX) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.50 (10.09% downside)

Analysts' Ratings History for Iridex Corp. (NASDAQ:IRIX)
DateFirmActionRatingPrice TargetDetails
1/26/2016Singular ResearchInitiated CoverageBuy$11.50View Rating Details
(Data available from 10/24/2014 forward)


Earnings History for Iridex Corp. (NASDAQ:IRIX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216$0.01($0.03)$11.90 million$11.90 millionViewListenView Earnings Details
5/5/2016Q116$0.04$0.01$11.88 million$11.90 millionViewListenView Earnings Details
3/3/2016Q415$0.04$0.04$11.80 million$12.10 millionViewListenView Earnings Details
11/5/2015Q315$0.04$10.10 million$9.80 millionViewListenView Earnings Details
8/6/2015Q215($0.07)$10.60 million$9.00 millionViewListenView Earnings Details
5/7/2015Q115$0.02$10.30 million$10.80 millionViewListenView Earnings Details
3/5/2015Q414$0.97$10.60 million$11.80 millionViewListenView Earnings Details
5/1/2014Q1$0.06$0.05$8.90 million$10.30 millionViewListenView Earnings Details
2/27/2014Q4$0.04$0.04ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Iridex Corp. (NASDAQ:IRIX)
Current Year EPS Consensus Estimate: $-0.03 EPS
Next Year EPS Consensus Estimate: $0.29 EPS


Dividend History for Iridex Corp. (NASDAQ:IRIX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Iridex Corp. (NASDAQ:IRIX)
Insider Ownership Percentage: 26.40%
Institutional Ownership Percentage: 42.94%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/12/2016Romeo R DizonInsiderSell125$15.00$1,875.00View SEC Filing  
9/7/2016Ruediger Naumann-EtienneDirectorSell9,513$14.75$140,316.75View SEC Filing  
9/2/2016Ruediger Naumann-EtienneDirectorSell2,513$14.73$37,016.49View SEC Filing  
8/23/2016Romeo R DizonInsiderSell875$14.52$12,705.00View SEC Filing  
8/19/2016Romeo R DizonInsiderSell7,896$13.52$106,753.92View SEC Filing  
8/16/2016George R MarcellinoDirectorSell2,513$13.57$34,101.41View SEC Filing  
8/16/2016Romeo R DizonInsiderSell839$13.70$11,494.30View SEC Filing  
6/6/2016Ronald SteckelVPSell625$13.52$8,450.00View SEC Filing  
5/17/2016Ronald SteckelVPSell4,583$12.81$58,708.23View SEC Filing  
3/8/2016Ronald SteckelVPSell12,000$10.45$125,400.00View SEC Filing  
11/19/2015William M MooreCEOBuy10,000$9.83$98,300.00View SEC Filing  
9/25/2015Associates & Paragon A ParagonMajor ShareholderBuy52,042$7.05$366,896.10View SEC Filing  
9/10/2015Associates & Paragon A ParagonMajor ShareholderBuy11,866$6.95$82,468.70View SEC Filing  
9/4/2015Associates & Paragon A ParagonMajor ShareholderBuy10,304$6.81$70,170.24View SEC Filing  
9/2/2015Ronald SteckelVPSell1,875$6.80$12,750.00View SEC Filing  
8/21/2015Associates & Paragon A ParagonMajor ShareholderBuy20,651$7.16$147,861.16View SEC Filing  
8/19/2015James H. MackanessCFOSell2,373$7.15$16,966.95View SEC Filing  
8/19/2015Ronald SteckelVPSell1,751$7.14$12,502.14View SEC Filing  
8/18/2015James H. MackanessCFOSell2,627$7.10$18,651.70View SEC Filing  
8/17/2015James H. MackanessCFOSell2,235$7.05$15,756.75View SEC Filing  
8/14/2015James H MackanessCFOSell7,765$6.99$54,277.35View SEC Filing  
8/14/2015Ronald SteckelVPSell1,458$7.00$10,206.00View SEC Filing  
7/24/2015Associates & Paragon A ParagonMajor ShareholderBuy40,403$7.01$283,225.03View SEC Filing  
6/17/2015Ronald SteckelVPSell1,666$8.77$14,610.82View SEC Filing  
5/20/2015James H MackanessCFOSell2,000$9.80$19,600.00View SEC Filing  
5/18/2015Ronald SteckelVPSell1,667$9.33$15,553.11View SEC Filing  
4/20/2015Ronald SteckelVPSell1,447$9.79$14,166.13View SEC Filing  
4/17/2015Ronald SteckelVPSell1,667$9.86$16,436.62View SEC Filing  
3/17/2015Ronald SteckelVPSell11,358$10.08$114,488.64View SEC Filing  
3/10/2015Ronald SteckelVPSell1,250$10.03$12,537.50View SEC Filing  
2/17/2015Ronald SteckelVPSell1,650$9.79$16,153.50View SEC Filing  
1/20/2015Ronald SteckelVPSell1,650$9.03$14,899.50View SEC Filing  
12/17/2014Ronald SteckelVPSell1,650$8.52$14,058.00View SEC Filing  
11/17/2014Ronald SteckelVPSell1,650$8.28$13,662.00View SEC Filing  
11/6/2014William M MooreDirectorBuy5,000$7.79$38,950.00View SEC Filing  
10/12/2014Catalyst Fund Ix L.P BluelineDirectorBuy17,237$8.11$139,792.07View SEC Filing  
10/10/2014Catalyst Fund Ix L.P BluelineDirectorBuy12,798$8.02$102,639.96View SEC Filing  
9/5/2014Catalyst Fund Ix L.P BluelineDirectorBuy8,432$7.99$67,371.68View SEC Filing  
8/29/2014Catalyst Fund Ix L.P BluelineDirectorBuy4,272$7.92$33,834.24View SEC Filing  
8/22/2014James B HawkinsDirectorSell600$8.03$4,818.00View SEC Filing  
8/18/2014Ronald SteckelVPSell1,650$8.00$13,200.00View SEC Filing  
8/15/2014James B HawkinsDirectorSell14,400$8.10$116,640.00View SEC Filing  
8/14/2014James B HawkinsDirectorSell2,714$8.08$21,929.12View SEC Filing  
8/13/2014James B HawkinsDirectorSell9,786$8.11$79,364.46View SEC Filing  
8/11/2014Garrett A GarrettsonDirectorSell2,810$8.30$23,323.00View SEC Filing  
7/31/2014Ronald SteckelVPSell761$8.00$6,088.00View SEC Filing  
7/21/2014James H MackanessCFOSell1,000$7.62$7,620.00View SEC Filing  
6/23/2014James H MackanessCFOSell2,000$8.24$16,480.00View SEC Filing  
6/17/2014Ronald SteckelVPSell1,650$8.20$13,530.00View SEC Filing  
6/6/2014Catalyst Fund Ix L.P BluelineDirectorBuy7,390$8.32$61,484.80View SEC Filing  
6/3/2014William M MooreCEOBuy5,000$8.48$42,400.00View SEC Filing  
5/21/2014James H MackanessCFOSell3,000$8.73$26,190.00View SEC Filing  
5/19/2014Ronald SteckelVPSell1,650$8.82$14,553.00View SEC Filing  
5/9/2014William M MooreCEOBuy5,000$8.40$42,000.00View SEC Filing  
4/22/2014James H MackanessCFOSell4,000$8.74$34,960.00View SEC Filing  
4/17/2014Ronald SteckelVPSell1,650$8.88$14,652.00View SEC Filing  
3/21/2014James H MackanessCFOSell4,000$9.03$36,120.00View SEC Filing  
3/17/2014Ronald SteckelVPSell1,650$9.07$14,965.50View SEC Filing  
2/18/2014Ronald SteckelVPSell1,650$8.60$14,190.00View SEC Filing  
1/17/2014Ronald SteckelVPSell1,650$10.42$17,193.00View SEC Filing  
12/17/2013Ronald SteckelVPSell1,650$8.56$14,124.00View SEC Filing  
12/2/2013James H MackanessCFOSell10,000$10.52$105,200.00View SEC Filing  
9/6/2013Ruediger Naumann-EtienneDirectorBuy3,600$5.99$21,564.00View SEC Filing  
8/9/2013William M MooreCEOBuy10,000$5.88$58,800.00View SEC Filing  
6/19/2013Eduardo AriasVPSell22,768$5.43$123,630.24View SEC Filing  
6/18/2013James H MackanessCFOSell19,862$4.58$90,967.96View SEC Filing  
6/17/2013Eduardo AriasVPSell4,532$5.39$24,427.48View SEC Filing  
6/14/2013James H MackanessCFOSell10,568$5.38$56,855.84View SEC Filing  
6/13/2013James H MackanessCFOSell1,400$5.30$7,420.00View SEC Filing  
6/11/2013Eduardo AriasVPSell1,000$5.61$5,610.00View SEC Filing  
6/11/2013James H MackanessCFOSell1,200$5.61$6,732.00View SEC Filing  
6/10/2013Eduardo AriasVPSell2,400$5.38$12,912.00View SEC Filing  
6/10/2013James H MackanessCFOSell6,970$5.36$37,359.20View SEC Filing  
6/6/2013William M MooreCEOBuy2,000$5.42$10,840.00View SEC Filing  
5/17/2013Eduardo AriasVPSell10,000$6.30$63,000.00View SEC Filing  
3/8/2013Ruediger Naumann-EtienneDirectorBuy2,400$4.80$11,520.00View SEC Filing  
3/7/2013William M MooreCEOBuy10,000$4.66$46,600.00View SEC Filing  
9/6/2012William M MooreCEOBuy10,000$3.76$37,600.00View SEC Filing  
8/15/2012Catalyst Fund Ix L.P BluelineMajor ShareholderBuy60,900$3.19$194,271.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Iridex Corp. (NASDAQ:IRIX)
DateHeadline logoIRIDEX Announces Preliminary Revenues for 2016 Third Quarter (NASDAQ:IRIX) - October 12 at 5:41 PM logoIridex Corp (IRIX) Prelim. Q3 Revenue Misses Expectations (NASDAQ:IRIX) - October 12 at 5:41 PM logoIRIDEX Corporation (NASDAQ:IRIX) Files An 8-K (NASDAQ:IRIX) - October 12 at 5:41 PM logoHumana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday (NASDAQ:IRIX) - October 12 at 5:41 PM logoIRIDEX : Announces Long-Term Glaucoma Efficacy Data for Patients Treated with MicroPulse® P3 Probe Technology (NASDAQ:IRIX) - September 17 at 10:13 AM logoIRIDEX Announces Long-Term Glaucoma Efficacy Data for Patients Treated with MicroPulse® P3 Probe Technology (NASDAQ:IRIX) - September 7 at 9:06 AM logoETF’s with exposure to IRIDEX Corp. : August 24, 2016 (NASDAQ:IRIX) - August 24 at 5:34 PM
News IconPrincipal Accounting Officer of IRIDEX Corporation (NASDAQ:IRIX), Dizon Romeo R, sells 1,690 shares worth $22,817 (NASDAQ:IRIX) - August 23 at 5:53 PM logoEdited Transcript of IRIX earnings conference call or presentation 4-Aug-16 9:00pm GMT (NASDAQ:IRIX) - August 15 at 9:16 PM logoIRIDEX Corp. :IRIX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 (NASDAQ:IRIX) - August 15 at 3:49 PM logoIridex Has Returned 51.7% Since SmarTrend Recommendation (IRIX) (NASDAQ:IRIX) - August 9 at 5:50 PM logoIRIDEX Corporation: IRIDEX Reports 2016 Second Quarter, Six-Month Results (NASDAQ:IRIX) - August 5 at 8:44 AM logoIridex reports 2Q loss (NASDAQ:IRIX) - August 5 at 8:44 AM logoQ2 2016 IRIDEX Corp Earnings Release - After Market Close (NASDAQ:IRIX) - August 4 at 8:44 AM logoIRIDEX Announces Second Quarter 2016 Conference Call and Release Date (NASDAQ:IRIX) - July 28 at 4:18 PM logoETF’s with exposure to IRIDEX Corp. : July 21, 2016 (NASDAQ:IRIX) - July 21 at 2:09 PM logoIRIDEX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agre (NASDAQ:IRIX) - July 11 at 4:17 PM logoIRIDEX Announces Atabak Mokari Will Be Chief Financial Officer And VP Corporate Development (NASDAQ:IRIX) - July 11 at 7:03 AM logoIRIDEX CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:IRIX) - June 21 at 4:17 PM logoIRIDEX to Present at the Singular Research 11th Annual Best of the Uncovereds Spring Select Conference (NASDAQ:IRIX) - June 2 at 4:35 PM logoInvestors’ Pick for May 20 – PQ, AQMS, BRC, IRIX, USMD, DWSN, UNB (NASDAQ:IRIX) - May 20 at 11:43 AM logoIRIDEX Corp. :IRIX-US: Earnings Analysis: Q1, 2016 By the Numbers (NASDAQ:IRIX) - May 11 at 11:57 AM logoIRIDEX Announces Cyclo G6™ with MicroPulse® P3 Clinical Data Presented at ARVO and ASCRS Annual Meetings (NASDAQ:IRIX) - May 10 at 7:18 AM logoIridex posts 1Q profit (NASDAQ:IRIX) - May 5 at 6:24 PM logoIRIDEX Reports 2016 First Quarter Results (NASDAQ:IRIX) - May 5 at 4:05 PM logoQ1 2016 IRIDEX Corp Earnings Release - After Market Close (NASDAQ:IRIX) - May 5 at 7:07 AM logoIRIDEX Announces First Quarter 2016 Conference Call and Release Date (NASDAQ:IRIX) - April 28 at 4:36 PM logoIRIDEX CORP Files SEC form 10-K, Annual Report (NASDAQ:IRIX) - March 31 at 5:20 PM logoIRIDEX Gains Patent Approvals Covering TxCell™-Guided MicroPulse® Laser Therapy; Predictably Enables Faster, Durable Treatments for Glaucoma and Retinal Diseases (NASDAQ:IRIX) - March 22 at 4:31 PM logo4:07 pm IRIDEX gains 2 patent approvals covering TXcell-guided micropulse laser therapy, enables treatments for glaucoma and retinal diseases (NASDAQ:IRIX) - March 22 at 4:07 PM logoETF’s with exposure to IRIDEX Corp. : March 10, 2016 (NASDAQ:IRIX) - March 10 at 1:54 PM logoIRIDEX Corp. :IRIX-US: Earnings Analysis: 2015 By the Numbers (NASDAQ:IRIX) - March 9 at 12:03 PM logoIRIDEX CORP Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:IRIX) - March 7 at 5:17 PM logoEdited Transcript of IRIX earnings conference call or presentation 3-Mar-16 10:00pm GMT (NASDAQ:IRIX) - March 4 at 2:47 PM logoIridex posts 4Q profit (NASDAQ:IRIX) - March 3 at 5:20 PM logoIRIDEX Corp Earnings Call scheduled for 5:00 pm ET today (NASDAQ:IRIX) - March 3 at 5:00 PM logoIRIDEX Reports 2015 Fourth Quarter, Full Year Results (NASDAQ:IRIX) - March 3 at 4:05 PM logoQ4 2015 IRIDEX Corp Earnings Release - After Market Close (NASDAQ:IRIX) - March 3 at 7:07 AM logoIRIDEX Receives CE Mark for Cyclo G6™ Laser System for the Treatment of Multiple Stages of Glaucoma (NASDAQ:IRIX) - February 16 at 6:30 AM logoCoverage initiated on IRIDEX by Singular Research (NASDAQ:IRIX) - January 26 at 2:15 PM logoIRIDEX CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:IRIX) - January 12 at 4:04 PM logoIRIDEX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:IRIX) - January 11 at 4:04 PM logoIRIDEX Announces Preliminary Unaudited Revenues for 2015 Fourth Quarter and Full Year (NASDAQ:IRIX) - January 11 at 6:47 AM logoEdited Transcript of IRIX earnings conference call or presentation 5-Nov-15 10:00pm GMT (NASDAQ:IRIX) - January 8 at 12:00 PM logoIRIDEX Corp. Earnings Analysis: Q3, 2015 By the Numbers (NASDAQ:IRIX) - December 21 at 12:24 PM logoIRIDEX CORP Financials (NASDAQ:IRIX) - December 8 at 1:17 PM logoTechnical Movement Driving Equities - Research on BIND Therapeutics, Edgewater Technology, IRIDEX, and PRGX Global (NASDAQ:IRIX) - December 2 at 8:30 AM logoDo Hedge Funds Love IRIDEX Corporation (IRIX)? (NASDAQ:IRIX) - December 1 at 5:29 PM logoIRIDEX to Showcase Cyclo G6™ Laser System Equipped with MicroPulse® Tissue Sparing Glaucoma Technology at American Academy of Ophthalmology (AAO) Meeting (NASDAQ:IRIX) - November 11 at 6:56 AM logoIRIDEX CORP Files SEC form 10-Q, Quarterly Report (NASDAQ:IRIX) - November 10 at 5:05 PM


Iridex Corp. (NASDAQ:IRIX) Chart for Monday, October, 24, 2016

Last Updated on 10/24/2016 by Staff